A Deal A Month? After Dusa, India’s Sun Bags URL’s Generics Business As Takeda Keeps Colcrys
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma continues its acquisition spree in the U.S. under new Chairman Israel Makov.
You may also be interested in...
Sun Finally Gains Control Of Taro As Founders Relent; Charts Out Aggressive Investment And Growth Plans
HYDERABAD - Bound by Israel's Supreme Court verdict earlier this month, drug firm Taro's founders - the Levitt and Moros families - have finally conceded management control of the 60-year old company that specializes in dermatology products to Sun Pharma - India's largest company by market capitalization
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.